-
公开(公告)号:US08389764B2
公开(公告)日:2013-03-05
申请号:US12480348
申请日:2009-06-08
申请人: Christopher Kallus , Mark Broenstrup , Werngard Czechtizky , Andreas Evers , Markus Follmann , Nis Halland , Herman Schreuder
发明人: Christopher Kallus , Mark Broenstrup , Werngard Czechtizky , Andreas Evers , Markus Follmann , Nis Halland , Herman Schreuder
IPC分类号: C07C275/00 , C07C273/00 , C07C331/00 , C07C381/00
CPC分类号: A61K31/4164 , A61K31/17 , A61K31/18 , A61K31/198 , A61K31/223 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/4184 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/4465 , A61K45/06 , C07C307/06 , C07D207/06 , C07D209/20 , C07D211/34 , C07D211/58 , C07D213/40 , C07D213/55 , C07D213/73 , C07D235/14 , C07D261/08 , C07D295/185 , C07D317/58 , C07D333/20 , C07D487/08 , A61K2300/00
摘要: The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及本文定义的式I化合物,其为活化凝血酶可激活的纤维蛋白溶解抑制剂的抑制剂。 式I的化合物适用于制备用于预防,二次预防和治疗与血栓形成,栓塞,高凝状态或纤维变性相关的一种或多种病症的药物。
-
公开(公告)号:US20100035930A1
公开(公告)日:2010-02-11
申请号:US12480348
申请日:2009-06-08
申请人: Christopher KALLUS , Mark BROENSTRUP , Werngard CZECHTIZKY , Andreas EVERS , Markus FOLLMANN , Nis HALLAND , Herman SCHREUDER
发明人: Christopher KALLUS , Mark BROENSTRUP , Werngard CZECHTIZKY , Andreas EVERS , Markus FOLLMANN , Nis HALLAND , Herman SCHREUDER
IPC分类号: A61K31/195 , A61K31/27 , A61K31/42 , A61K31/40 , A61K31/381 , A61K31/4402 , A61K31/44 , A61K31/445 , A61P7/00 , C07C271/22 , C07C229/12 , C07D261/08 , C07D207/09 , C07D333/22 , C07D213/56 , C07D211/56
CPC分类号: A61K31/4164 , A61K31/17 , A61K31/18 , A61K31/198 , A61K31/223 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/4184 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/4465 , A61K45/06 , C07C307/06 , C07D207/06 , C07D209/20 , C07D211/34 , C07D211/58 , C07D213/40 , C07D213/55 , C07D213/73 , C07D235/14 , C07D261/08 , C07D295/185 , C07D317/58 , C07D333/20 , C07D487/08 , A61K2300/00
摘要: The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及本文定义的式I化合物,其为活化凝血酶可激活的纤维蛋白溶解抑制剂的抑制剂。 式I的化合物适用于制备用于预防,二次预防和治疗与血栓形成,栓塞,高凝状态或纤维变性相关的一种或多种病症的药物。
-
3.
公开(公告)号:US20140206760A1
公开(公告)日:2014-07-24
申请号:US14226132
申请日:2014-03-26
申请人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
发明人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
IPC分类号: C07D413/12 , C07D267/00 , C07D273/02 , C07D273/01
CPC分类号: C07D273/01 , A61K31/395 , C07D267/00 , C07D273/02 , C07D413/12 , C07D413/14
摘要: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes.
摘要翻译: 本发明涉及作为活化凝血酶激活性纤维蛋白溶解抑制剂抑制剂的式(I)化合物。 式I的化合物适用于制备用于预防,二次预防和治疗与血栓形成,栓塞,高渗透性或纤维变性相关的一种或多种病症的药物。
-
4.
公开(公告)号:US08580777B2
公开(公告)日:2013-11-12
申请号:US12996460
申请日:2009-05-22
申请人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
发明人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
IPC分类号: C07D413/14 , C07D273/01 , A61K31/553 , A61P7/00
CPC分类号: C07D273/01 , A61K31/395 , C07D267/00 , C07D273/02 , C07D413/12 , C07D413/14
摘要: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及作为活化凝血酶激活性纤维蛋白溶解抑制剂抑制剂的式(I)化合物。 式I的化合物适用于制备用于预防,二次预防和治疗与血栓形成,栓塞,高凝状态或纤维变性相关的一种或多种病症的药物。
-
公开(公告)号:US08476222B2
公开(公告)日:2013-07-02
申请号:US12417307
申请日:2009-04-02
申请人: Gerhard Seibert , László Vértesy , Joachim Wink , Irvin Winkler , Mark Broenstrup , Holger Hoffmann , Hans Guehring , Luigi Toti , Roderich Süssmuth , George M. Sheldrick , Kathrin Meindl
发明人: Gerhard Seibert , László Vértesy , Joachim Wink , Irvin Winkler , Mark Broenstrup , Holger Hoffmann , Hans Guehring , Luigi Toti , Roderich Süssmuth , George M. Sheldrick , Kathrin Meindl
摘要: The disclosure relates to a compound of the formula (I) wherein R1 is H, C(O)—(C1-C6)alkyl or C(O)—O—(C1-C6)alkyl; R2 is OH, NH2, NH—(C1-C6)alkyl, NH—(C1-C4)alkylene-phenyl or NH—(C1-C4)alkylene-pyridyl; R3 and R4 are independently of each other H or OH, or R3 and R4 together are ═O; and m and n are independently of one another 0, 1 or 2; in any stereochemical form, or a mixture of any stereochemical forms in any ratio, or a physiologically acceptable salt thereof, obtainable from Actinomadura namibiensis (DSM 6313), and its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.
摘要翻译: 本发明涉及式(I)化合物,其中R 1是H,C(O) - (C 1 -C 6)烷基或C(O)-O-(C 1 -C 6)烷基; R2是OH,NH2,NH-(C1-C6)烷基,NH-(C1-C4)亚烷基 - 苯基或NH-(C1-C4)亚烷基 - 吡啶基; R3和R4彼此独立地为H或OH,或R3和R4一起为= O; m和n彼此独立地为0,1或2; 任何立体化学形式,或任何比例的任何立体化学形式的混合物,或其生理学上可接受的盐,可从放线杆菌素(DSM 6313)获得,以及其用于治疗细菌感染,病毒感染和/或疼痛的用途,以及 包含它的药物组合物。
-
公开(公告)号:US20090298904A1
公开(公告)日:2009-12-03
申请号:US12417307
申请日:2009-04-02
申请人: Gerhard Seibert , László Vértesy , Joachim Wink , Irvin Winkler , Mark Broenstrup , Holger Hoffmann , Hans Guehring , Luigi Toti , Roderich Süssmuth , George M. Sheldrick , Kathrin Meindl
发明人: Gerhard Seibert , László Vértesy , Joachim Wink , Irvin Winkler , Mark Broenstrup , Holger Hoffmann , Hans Guehring , Luigi Toti , Roderich Süssmuth , George M. Sheldrick , Kathrin Meindl
IPC分类号: A61K31/40 , C07D513/18 , C12P17/18
摘要: The disclosure relates to a compound of the formula (I) wherein m and n are independently of one another 0, 1 or 2, obtainable from Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.
摘要翻译: 本公开涉及式(I)的化合物,其中m和n彼此独立地为0,1或2,可从放线菌素(DSM 6313)获得,其用于治疗细菌感染,病毒感染和/或 疼痛和包含它的药物组合物。
-
7.
公开(公告)号:US08722655B2
公开(公告)日:2014-05-13
申请号:US14048339
申请日:2013-10-08
申请人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
发明人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
IPC分类号: C07D413/14 , C07D273/01 , A61K31/553 , A61P7/00
CPC分类号: C07D273/01 , A61K31/395 , C07D267/00 , C07D273/02 , C07D413/12 , C07D413/14
摘要: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及作为活化凝血酶激活性纤维蛋白溶解抑制剂抑制剂的式(I)化合物。 式I的化合物适用于制备用于预防,二次预防和治疗与血栓形成,栓塞,高凝状态或纤维变性相关的一种或多种病症的药物。
-
8.
公开(公告)号:US20140039011A1
公开(公告)日:2014-02-06
申请号:US14048339
申请日:2013-10-08
申请人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
发明人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
IPC分类号: C07D273/02 , C07D413/12 , C07D273/01
CPC分类号: C07D273/01 , A61K31/395 , C07D267/00 , C07D273/02 , C07D413/12 , C07D413/14
摘要: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及作为活化凝血酶激活性纤维蛋白溶解抑制剂抑制剂的式(I)化合物。 式I的化合物适用于制备用于预防,二次预防和治疗与血栓形成,栓塞,高凝状态或纤维变性相关的一种或多种病症的药物。
-
9.
公开(公告)号:US20110178130A1
公开(公告)日:2011-07-21
申请号:US12996460
申请日:2009-05-22
申请人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
发明人: Christopher Kallus , Mark Broenstrup , Andreas Evers , Anja Globisch , Herman Schreuder , Michael Wagner
IPC分类号: A61K31/395 , C07D273/01 , A61K31/4427 , C07D273/08 , A61P9/10 , A61P7/02 , A61P29/00 , A61P3/04 , A61P35/00 , A61P27/02 , A61P17/02
CPC分类号: C07D273/01 , A61K31/395 , C07D267/00 , C07D273/02 , C07D413/12 , C07D413/14
摘要: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及作为活化凝血酶激活性纤维蛋白溶解抑制剂抑制剂的式(I)化合物。 式I的化合物适用于制备用于预防,二次预防和治疗与血栓形成,栓塞,高凝状态或纤维变性相关的一种或多种病症的药物。
-
10.
公开(公告)号:US20110144001A1
公开(公告)日:2011-06-16
申请号:US12895106
申请日:2010-09-30
申请人: Mark BROENSTRUP , Hans GUEHRING , Holger HOFFMANN , Joachim WINK , Roderich SUESSMUTH , Timo SCHMIEDERER
发明人: Mark BROENSTRUP , Hans GUEHRING , Holger HOFFMANN , Joachim WINK , Roderich SUESSMUTH , Timo SCHMIEDERER
摘要: The invention refers to so-called Labyrinthopeptin derivatives of the formula (I) wherein {A}, {B}, {C}, R1-R6, m and n are as defined herein, obtainable from microorganism strain Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, a pharmaceutical composition comprising it, prepro-Labyrinthopeptin, pro-Labyrinthopeptin, and DNA coding for prepro-Labyrinthopeptin and pro-Labyrinthopeptin.
摘要翻译: 本发明涉及可从微生物菌株放线菌(Actinomadura namibiensis)(DSM 6313)获得的所谓的式(I)的赖氨维内肽衍生物,其中{A},{B},{C},R1-R6,m和n如本文所定义 ,其用于治疗细菌感染,病毒感染和/或疼痛的药物组合物,包含其的药物组合物,前体Labyrinthopeptin,前Labyrinthopeptin和编码前LabLinhopeptin和亲Labyrinthopeptin的DNA。
-
-
-
-
-
-
-
-
-